Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIR-201 Extension Study
NCT00332930Phase 2Completed
- Sponsor
- The Kirby Institute
- Start
- Sep 2002
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Conjugated siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing VIR-201, rFPV-HIV gag-pol and Placebo (3 arms). Primary endpoint: Time weighted area under the curve change from plasma HIV-RNA VL. Started Sep 2002; status: completed.
02
Drugs
VIR-201VIR201
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00332930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00332930.